Byetta Needs More Studies To Determine Pancreatitis Risks, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The previously undisclosed requirements are a setback to Amylin and Lilly, which jointly market the drug and plan a once-weekly version.
You may also be interested in...
Medco Study Lets Januvia And Byetta Off The Hook For Pancreatitis
Pharmaceutical benefits manager's review of almost 800,000 claims does not show higher risk for these two drugs, despite label warnings.
Medco Study Lets Januvia And Byetta Off The Hook For Pancreatitis
Pharmaceutical benefits manager's review of almost 800,000 claims does not show higher risk for these two drugs, despite label warnings.
FDA's Handling Of Byetta Pancreatitis Risk Could Bode Well For Other Diabetes Drugs
Amylin's Byetta cleared for first-line use without a black box stigma, but sales may still not get a lift.